Alloy Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
137
- Latest Deal Type
-
Series E
- Latest Deal Amount
-
$40M
- Investors
-
25
Alloy Therapeutics General Information
Description
Developer of a product development platform designed to help biotechnology companies, pharmaceutical organizations, academic founders, and sovereign institutions discover and develop medicines. The company's platform offers proprietary technology, artificial intelligence, real-world data, and integrated capabilities across antibody and multispecific development, TCR mimics, genetic medicines, cell therapies, pharmacology, and clinical development, enabling partner-owned drug programs to progress from early research toward clinical development and commercialization.
Contact Information
Website
www.alloytx.comCorporate Office
- 275 Second Avenue
- Suite 200
- Waltham, MA 02451
- United States
Corporate Office
- 275 Second Avenue
- Suite 200
- Waltham, MA 02451
- United States
Alloy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series E) | 31-Mar-2026 | $40M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series D) | 16-Sep-2022 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jun-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 02-Apr-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 10-May-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 15-May-2019 | $6M | $6M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Alloy Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E2 | ||||||||
| Series E1 | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | 1,949,906 | $0.000100 | $0.77 | $0.77 | 1x | $0.77 | 5.1% | |
| Series A1 | 1,444,374 | $0.000100 | $0.35 | $0.35 | 1x | $0.35 | 3.78% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Alloy Therapeutics Comparisons
Industry
Financing
Details
Alloy Therapeutics Competitors (30)
One of Alloy Therapeutics’s 30 competitors is BioLegend, a Formerly Accelerator/Incubator backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioLegend | Formerly Accelerator/Incubator backed | San Diego, CA | ||||
| ProSci (Biotechnology) | Private Equity-Backed | Poway, CA | ||||
| Abcam | Corporate Backed or Acquired | Cambridge, United Kingdom | ||||
| Creative Biolabs | Corporation | Shirley, NY | ||||
| Regis Technologies | Formerly VC-backed | Morton Grove, IL |
Alloy Therapeutics Patents
Alloy Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026174257-A1 | Production of anitgen-reactive vl antibodies in vivo | Pending | 13-Feb-2025 | ||
| WO-2026170086-A1 | Anti-transferrin receptor 1 (anti-tfr1) antibodies, compositions, and methods for use in tfr1-mediated delivery of therapeutic payloads | Pending | 08-Feb-2025 | ||
| WO-2026055339-A1 | Methods for identifying cognate immunoglobulin pairs from individual b cells | Pending | 04-Sep-2024 | ||
| WO-2026006494-A1 | Anti-cd3 antibodies and uses thereof | Pending | 25-Jun-2024 | ||
| WO-2026006496-A1 | Anti-cd3 antibodies and uses thereof | Pending | 25-Jun-2024 | C07K16/2809 |
Alloy Therapeutics Signals
Alloy Therapeutics Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alumni Ventures | Venture Capital | Minority | ||
| Echo Capital | PE/Buyout | Minority | ||
| JIC Venture Growth Investments | Venture Capital | Minority | ||
| Germin8 Ventures | Venture Capital | Minority | ||
| Mubadala Capital | Asset Manager | Minority |
Alloy Therapeutics Investments & Acquisitions (15)
Alloy Therapeutics’s most recent deal was a Joint Venture with Developing Antibody Drug (Alloy Therapeutics / Tahoe). The deal was made on 13-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Developing Antibody Drug (Alloy Therapeutics / Tahoe) | 13-Jan-2026 | Joint Venture | Drug Discovery | ||
| Spannerwerks, An Alloy Therapeutics Company | 15-Oct-2025 | Merger/Acquisition | Biotechnology | ||
| Wheeler Bio | 20-Mar-2025 | Later Stage VC | Biotechnology | ||
| Aakha Biologics | 15-Apr-2024 | Seed Round | Drug Discovery | ||
| Cantai Therapeutics | 20-Nov-2023 | Seed Round | Drug Discovery |
Alloy Therapeutics Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Spannerwerks, An Alloy Therapeutics Company | Seattle, WA | 2015 | |
| Lanier Biotherapeutics | Jefferson, GA | 2000 | |
| 82VS | Boston, MA |
Alloy Therapeutics FAQs
-
When was Alloy Therapeutics founded?
Alloy Therapeutics was founded in 2017.
-
Where is Alloy Therapeutics headquartered?
Alloy Therapeutics is headquartered in Waltham, MA.
-
What is the size of Alloy Therapeutics?
Alloy Therapeutics has 137 total employees.
-
What industry is Alloy Therapeutics in?
Alloy Therapeutics’s primary industry is Discovery Tools (Healthcare).
-
Is Alloy Therapeutics a private or public company?
Alloy Therapeutics is a Private company.
-
What is the current valuation of Alloy Therapeutics?
The current valuation of Alloy Therapeutics is .
-
What is Alloy Therapeutics’s current revenue?
The current revenue for Alloy Therapeutics is .
-
How much funding has Alloy Therapeutics raised over time?
Alloy Therapeutics has raised $174M.
-
Who are Alloy Therapeutics’s investors?
Alumni Ventures, Echo Capital, JIC Venture Growth Investments, Germin8 Ventures, and Mubadala Capital are 5 of 25 investors who have invested in Alloy Therapeutics.
-
Who are Alloy Therapeutics’s competitors?
BioLegend, ProSci (Biotechnology), Abcam, Creative Biolabs, and Regis Technologies are some of the 30 competitors of Alloy Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process